Compare IPSC & BPRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPSC | BPRN |
|---|---|---|
| Founded | 2019 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 362.5M | 292.8M |
| IPO Year | 2021 | 2022 |
| Metric | IPSC | BPRN |
|---|---|---|
| Price | $2.12 | $43.13 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 452.3K | 19.6K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 3.93% |
| EPS Growth | ★ 91.30 | 74.84 |
| EPS | N/A | ★ 1.95 |
| Revenue | ★ $109,164,000.00 | N/A |
| Revenue This Year | N/A | $9.96 |
| Revenue Next Year | N/A | $6.13 |
| P/E Ratio | ★ N/A | $22.04 |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $29.70 |
| 52 Week High | $2.97 | $43.93 |
| Indicator | IPSC | BPRN |
|---|---|---|
| Relative Strength Index (RSI) | 51.77 | 63.51 |
| Support Level | $1.88 | $41.35 |
| Resistance Level | $2.39 | $43.85 |
| Average True Range (ATR) | 0.09 | 0.90 |
| MACD | 0.01 | -0.12 |
| Stochastic Oscillator | 61.11 | 64.40 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Princeton Bancorp Inc is a full-service financial institution providing personal and business banking services, including checking and savings accounts, as well as a range of lending products such as residential, commercial, construction, and consumer loans, including home equity loans and lines of credit. The Bank operates branches and conducts loan origination activities in areas of the New York City metropolitan area. Its loan portfolio is segmented into commercial real estate (including owner-occupied, non-owner-occupied, and multi-family properties), construction loans (mainly for residential developments), commercial and industrial loans (for business purposes), residential real estate loans (secured by one-to-four family properties), and consumer/HELOC loans.